DYNE THERAPEUTICS INC (DYN)

US26818M1080 - Common Stock

15  -0.29 (-1.9%)

After market: 15 0 (0%)

Buy % Consensus

86

ChartMill assigns a Buy % Consensus number of 86% to DYN. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 51.43. This target is 242.83% above the current price.
DYN was analyzed by 16 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about DYN.
In the previous month the buy percentage consensus was at a similar level.
DYN was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 15.0034.3451.0051.4369.30 - 128.93% 240.00% 242.83% 362.00%
Up and Down Grades
Date Firm Action Rating
2025-01-14 RBC Capital Reiterate Outperform -> Outperform
2025-01-13 HC Wainwright & Co. Reiterate Buy -> Buy
2025-01-10 Chardan Capital Maintains Buy -> Buy
2025-01-10 HC Wainwright & Co. Reiterate Buy -> Buy
2024-12-13 Baird Initiate Outperform
2024-11-26 RBC Capital Initiate Outperform
2024-11-13 Chardan Capital Maintains Buy -> Buy
2024-11-13 HC Wainwright & Co. Reiterate Buy -> Buy
2024-10-24 JP Morgan Downgrade Overweight -> Neutral
2024-09-23 Piper Sandler Reiterate Overweight -> Overweight
2024-09-04 HC Wainwright & Co. Reiterate Buy -> Buy
2024-09-03 Oppenheimer Reiterate Outperform -> Outperform
2024-08-16 Stifel Maintains Buy -> Buy
2024-08-15 Guggenheim Maintains Buy -> Buy
2024-08-14 Morgan Stanley Maintains Overweight -> Overweight
2024-08-13 Piper Sandler Maintains Overweight -> Overweight
2024-08-13 HC Wainwright & Co. Maintains Buy -> Buy
2024-07-09 JP Morgan Maintains Overweight -> Overweight
2024-05-21 Chardan Capital Maintains Buy -> Buy
2024-05-20 Jefferies Maintains Buy -> Buy
2024-05-20 HC Wainwright & Co. Maintains Buy -> Buy
2024-05-06 Chardan Capital Maintains Buy -> Buy
2024-05-06 Oppenheimer Reiterate Outperform -> Outperform
2024-05-03 HC Wainwright & Co. Reiterate Buy -> Buy
2024-04-30 Morgan Stanley Initiate Overweight
2024-03-26 Oppenheimer Reiterate Outperform -> Outperform
2024-03-08 Chardan Capital Maintains Buy -> Buy
2024-03-07 Guggenheim Maintains Buy -> Buy
2024-03-06 Stifel Maintains Buy -> Buy
2024-03-06 Piper Sandler Maintains Overweight -> Overweight